Hormonal
Administration of the triple agonist peptide GEP44 to diet-induced obese rats produces greater reductions in body weight and food intake compared to the GLP-1 receptor agonist liraglutide, while avoiding the nausea and malaise associated with high-dose GLP-1RAs.
This preclinical data suggests that combining GLP-1 activity with Neuropeptide Y1 and Y2 receptor agonism may offer a path to more effective weight loss than current GLP-1 drugs alone, potentially without the common side effect of nausea. This is not yet a human treatment but highlights a promising direction for peptide-based obesity therapies.
The rats treated with GEP44 exhibited notably larger reductions in both body weight... and food intake... compared to rats treated with LIRA... By contrast, we were able to continue the dose escalation in rats treated with GEP44... with no indication of malaise.
Why this rating
Preclinical animal study (rats); not human clinical trial.
Source
A Peptide Triple Agonist of GLP-1, Neuropeptide Y1, and Neuropeptide Y2 Receptors Promotes Glycemic Control and Weight Loss
Kylie S. Chichura et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022
DOI 10.1101/2022.11.07.515458
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →